Progress in Diverse Parkinson’s Disease Therapeutics to be Focal Point at ASGCT Annual Meeting

The American Society of Gene & Cell Therapy (ASGCT) will highlight the emergence of the latest in Parkinson’s disease treatments during its 15th Annual Meeting taking place in Philadelphia, Pennsylvania May 16 – 19, 2012.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Milwaukee, WI (PRWEB) May 03, 2012

The American Society of Gene & Cell Therapy (ASGCT) will highlight the emergence of the latest in Parkinson’s disease treatments during its 15th Annual Meeting taking place in Philadelphia, Pennsylvania May 16 – 19, 2012.

Parkinson’s disease is a neurological disorder that occurs when the brain’s dopamine-producing cells degenerate and die, producing serious, life-threatening, dopamine-dependent motor deficits. With the absence of this required neurotransmitter, the body cannot properly function, resulting in progressive shaking, as well slowing and loss of voluntary motor function. According to the National Parkinson Foundation, Parkinson’s disease affects 1,000,000 patients and its prevalence is growing (http://www.parkinson.org/parkinson-s-disease.aspx).

Parkinson’s has been classified as one of ten targeted disease areas showing favorable response to genetic and cellular based therapeutic treatments by the Society. Among the various treatment approaches to be showcased is the unique dopamine replacement treatment, Prosavin®. Professor Stephane Palfi from the France based, Henri Mondor Hospital, will present clinical results on the gene injection method that produces an enzymatic response in the production of dopamine.

Abstract: 56
Title: ProSavin® a Gene Therapy Approach for Parkinson's Disease: Phase I Clinical Trial Update
Date: Thursday, May 17, 2012
Session Info: Simultaneous Oral Abstract Sessions: Clinical Gene & Cell Therapy Oral Abstract Session
Presentation Time: 3:00 p.m.
Room: Ballroom AB

Shin-ichi Muramatsufrom Jichi Medical University, in his lecture titled: AADC Gene Therapy for Parkinson’s disease: Results of 3-5 Years of Follow-Up, will speak on the promising results from a long-standing trial involving AADC encoding from intrastriatal infusion of recombinant AAV vector.

Date: Wednesday, May 16, 2012
Session Info: Scientific Symposium 102: Progress in Asia
Presentation Time: 8:00 a.m.
Room: 203 AB

Dr. Raymond Bartus of Ceregene, Inc. will present his lecture: The Development of AAV-2 neurturin (CERE-120) for Parkinson’s disease: A Review of the Challenges and Translational Issues Confronted During the Course of Establishing “Clinical Proof of Concept”. This session will explore this more mature gene transfer treatment involving over 120 Parkinson’s Disease patients, 80 of whom received CERE-120. The fourth trial in this 7 year series will document the progress in rejuvenating nigostriatal neurons.

Date: Thursday, May 17, 2012
Session Info: Scientific Symposium 211: Clinical Trials 1
Presentation Time: 11:00 a.m.
Room: Ballroom AB

The American Society of Gene & Cell Therapy (ASGCT) is a professional nonprofit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, http://www.asgct.org.


Contact